Post-Doctoral Fellow Position at Shanghai Institute of Materia Medica/Suzhou Xenofinder

中科院上海藥物研究所和蘇州銳迪歐公司招聘聯合培養藥物代謝博士后招聘簡介

 

本藥物代謝博士后培訓旨在為新藥研發企業培養急需的藥物代謝高端人才,共招2人,博士后在站2-3年。歡迎具有機化學基礎和高分辨質譜儀應用經驗的中國、美國博士申請,錄取者需要盡快開始博士后研究。

 

1. 專業介紹

藥物生物轉化 (Biotransformation)是藥物代謝和藥物動力學(DMPK)的一個重要分支,其研究內容主要是應用液相色譜-高分辨質譜聯用(LC-HRMS)和放射性同位素檢測技術發現、鑒定和定量分析體外和體內的代謝物。生物轉化研究目的是揭示藥物在體內的代謝清除途徑、代謝物的毒性、藥理作用和代謝酶介導的藥物相互作用(DDI)機理等。代謝物鑒定(Met ID)涉及到新藥研發全過程:從先導候選物代謝軟位點分析到臨床人體放射性ADME研究,所以大部分新藥研發企業需要具有生物轉化教育背景的高端人才。但是,由于多種原因,中國、美國很少有科研單位培養以Met ID為技術核心的藥物生物轉化博士和博士后。本藥物代謝博士后培訓和研究集中在新藥的生物轉化方面。

2.  應聘條件

  • 獲得DMPK、分析化學、藥物分析、天然藥物化學、藥物化學或相關專業博士學位;
  • 具有較好的有機化學基礎和較豐富的應用高分辨質譜儀的經驗;對DMPK學科和放射性同位素14C檢測有一定的了解;
  • 對在工業界從事新藥DMPK研究有很大興趣;具有獨立科研和寫作學術論文的能力和經驗;
  • 樂觀開朗、積極向上、具有團隊合作精神。

 

3. 研究方向研究方向

  • 應用LC-HRMS和放射性14C開展Met ID和研究生物轉化生成機理;
  • 應用體外、體內Met ID實驗模型和分析方法完成新藥DMPK研發項目;
  • 建立和發展新型藥物(ADC、PDC、PROTAC等)ADME研究的新策略和新方法;
  • 建立和發展各種非CYP代謝酶表型和酶動力學研究的模型和方法,并用于新藥的研發;
  • 協助課題組長申請基金、獨立申請博士后基金和其他基金。

 

4.工作地點和待遇

按照項目要求,工作地點在上?;蛘咛K州,博士后在站2-3年。按照中科院上海藥物所相關規定提供與學歷和經驗相匹配的有競爭力的待遇;承擔藥企新藥DMPK研發項目時,有績效補貼。博士后出站后,推薦申請在中資或跨國藥企開展與DMPK相關的工作。

 

5. 應聘方式

歡迎有志于在新藥DMPK研發的中國、美國博士申請。應聘者請將個人簡歷發至:This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.。標題注明“藥物代謝博士后”。應聘者Email中簡述對崗位的理解、個人職業規劃和期望待遇。對符合條件者盡快安排在ASMS會議期間面試或網上面試。ASMS會議上聯系方式:微信Mingshe2014。 招聘單位對應聘資料嚴格保密。本招聘啟事直到崗位招滿前一直有效。

 

6. 中科院上海藥物研究所刁星星課題組簡介

中國科學院上海藥物研究所藥物代謝研究中心是專注于新藥DMPK研究的教育、科研和項目服務的研究中心,其研究和服務范圍涵蓋藥物的ADME、體外DDI和生物分析。中心擁有現有多位研究員(教授)和先進的DMPK研究儀器和設備。承擔有973、863、國家自然科學基金等多項國家課題,與國內外100+ 家企業、20+ 家醫院建立了合作關系。積累了300余種創新藥物臨床前和臨床DMPK研究經驗。

刁星星研究員團隊有30余人,其中博士后3名、實驗室主管4名,研究范圍包括藥物的生物轉化、代謝酶表型、代謝物生成機理等。其實驗室具有開展Met ID和放射性ADME實驗的LC-HRMS和放射性檢測儀器。先后為國內外20+家藥企完成了30+項臨床前和人體放射性ADME試驗。

 

7. 蘇州銳迪歐醫藥科技有限公司簡介

蘇州銳迪歐醫藥科技有限公司(簡稱“銳迪歐”)位于江蘇省蘇州市工業園區中科蘇州藥物研究院,是專注于開展創新藥物Met ID和放射性ADME研究的服務平臺。核心團隊受過系統的藥物代謝教育和訓練,具有在美國和中國知名藥企、CRO和科研機構開展新藥研發的豐富經驗,曾參與、主導或指導完成了多項支持小分子新藥上市的ADME研究和各種新型藥物的代謝研究。

銳迪歐從支持新藥發現、開發和在中國及歐美日申報上市的角度,為全球新藥研發企業提供以Met ID和放射性ADME研究為核心的代謝物鑒定一站式服務。服務范圍涵蓋從早期發現階段的先導化合物優化、臨床前候選新藥的評估,到臨床階段的新藥開發。銳迪歐具有完備的開展Met ID和放射性ADME實驗的設備、能力和經驗,能夠開展各種新型藥物的代謝研究,并可根據需要提供特殊的研究策略和針對性的解決方案。

8. 博士后導師簡介

刁星星 研究員

Xingxing Diao received his PhD from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (Shanghai, China) in 2014 and completed his postdoctoral training in NIH (Baltimore, USA) in 2014-2016. He then worked in XenoBiotic Laboratories (Plainsboro, NJ, USA) and Celgene (Summit, NJ, USA) for 3 years prior to returning to China. In addition to leading XenoFinder, Dr. Diao is currently a professor at SIMM, where he established a comprehensive DMPK lab capable of conducting in vitro and in vivo metabolite profiling and identification, metabolizing enzyme phenotyping, animal PK, radiolabeled ADME studies in animals and human.

His PhD research focused on evaluating DMPK of 3-n-butylphthalide (NBP) in human, including human samples Met ID, quantification of NBP and 4 major metabolites, the metabolic bioactivation underlying the hepatotoxicity of NBP and the mechanism responsible for the isomer-selective distribution of 3-OH-NBP and 10-OH-NBP across blood-brain barrier.In NIH, he set up human hepatocyte incubation platform to study metabolism of new synthetic cannabinoid (SC) and developed strategies to analyze the use of new SCs for forensic investigation.In XenoBiotic Laboratories and Celgene, he conducted mainly biotransformation studies of new drug candidates, including metabolite profiling and identification using LC-HRMS and 14C-labeled ADME studies animals and human. In SIMM, Dr. Diao trains PhD candidates and postdocs, conducts mechanistic studies of drug biotransformation and investigative ADME research of new drug candidates. Dr. Diao published over 43 peer-reviewed research papers (29 papers are the first-author or corresponding author). (https://pubmed.ncbi.nlm.nih.gov/?term=Xingxing+Diao)

朱明社博士

Dr. Mingshe Zhu is an independent consultant to provide DMPK consultation services to biotech and pharma companies in China and USA (Mar 2017-present) in support of drug discovery, development, and regulatory submissions. He also served as the scientific advisor of DMPK Dept. at WuXi AppTec in Nanjing, China (Mar 2017-Dec 2021) with responsibilities of staff scientist training, developing new methods in ADME studies, technic marketing, key experimental design, data interpretation, and helping clients to solve program issues. He has involved in IND-enabling biotransformation and radiolabeled ADME studies in animals and human, which supported IND filing of many clinical candidates and NDA filings of over 10 drug candidates in China and USA, including the marketing approval of 5 new drugs (Anlotin, Ensartinib Hydrochloride, Fospropofol Disodium, Donafenib, Olverembatinib) in China.

Dr. Zhu previously worked in Dept. of Biotransformation, Bristol-Myers Squibb (BMS) for 19 years, where he and his team supported over 10 discovery programs, more than 15 development drug candidates, and the worldwide approvals of ABILIFY (Aripiprazole) and FORXIGA (Dapagliflozin). Dr. Zhu and his collaborators at BMS developed several innovative LC/MS workflows and data-mining technologies such as Mass Defect Filter, Background Subtraction and Multiple Reaction Monitoring for drug metabolite detection and identification, which are now routinely used in drug metabolism research worldwide. Recently, his research interests have been expanded to unconventional drug modalities, such as ADC, cyclic peptides, herbal medicines, covalent drugs, stable isotope labeled drugs, prodrugs, and protein therapeutics.

He received PhD in analytical toxicology at SUNY Albany and completed post-doctoral fellowship in drug metabolism at University of Washington. Dr. Zhu served the chair of ISSX focus group of “Bioanalysis in ADME Science” (2016-2018) and taught drug metabolism and mass spectrometry short courses at ASMS (2011-present), EAS (2002-2010) and ACS (2006, 2008). He co-edited two books, Drug Metabolism in Drug Design and Development and Mass Spectrometry in Drug Metabolism and Disposition and co-authored 100+ research articles (https://pubmed.ncbi.nlm.nih.gov/?term=Mingshe%20Zhu&sort=date).